Primary Sclerosing Cholangitis Clinical Trials

16 studies are recruiting for primary sclerosing cholangitis in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Unraveling the Mechanisms Underlying Primary Sclerosing Cholangitis Through a Multidisciplinary, Integrative Research Approach

   Background: Primary sclerosing cholangitis is a rare chronic liver disease. It affects the bile ducts of the liver. It can result in bile duct infections, cirrhosis, cancer, and end stage liver disease. Researchers want to learn more about this disease. Objective: To understand the biological cause…

   Stage

   Not phased

   Ages

   18 to 90

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

   See if you can join NCT04685200 on ClinicalTrials.gov

2. A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis

   The purpose of this study is to find out how well and safely elafibranor works compared to placebo in adult participants with Primary sclerosing cholangitis (PSC). PSC is a rare disease that causes inflammation and scarring of the bile ducts in the liver. Over time, this can lead to liver damage an…

   Stage

   Phase 3

   Ages

   18 to 75

   Site

   Arizona Liver Health, Chandler, Arizona

   Locations

   13 in total

   Run by

   Ipsen

   See if you can join NCT07387549 on ClinicalTrials.gov

3. MRI Based Biomarkers in Pediatric Autoimmune Liver Disease

   Autoimmune liver diseases (AILD), which include Primary Sclerosing Cholangitis (PSC) and Autoimmune Hepatitis (AIH) are a common etiological factors for chronic liver disease among adolescents. In all these conditions, autoimmune lymphocyte responses are thought to orchestrate inflammatory injury a…

   Stage

   Not phased

   Ages

   6 to 23

   Site

   Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio

   Run by

   Children's Hospital Medical Center, Cincinnati

   See if you can join NCT03175471 on ClinicalTrials.gov

4. MRI Biomarkers in as Predictor of Clinical Endpoints in Pediatric Autoimmune Liver Disease

   Autoimmune liver diseases (AILD), which include Primary Sclerosing Cholangitis (PSC) and Autoimmune Hepatitis (AIH) are a common etiological factor for chronic liver disease among adolescents. This is a longitudinal study to identify surrogate endpoints with an accurate predictive value for the pro…

   Stage

   Not phased

   Ages

   6 to 23

   Site

   Cincinnati Children's Hospital and Medical Center, Cincinnati, Ohio

   Run by

   Children's Hospital Medical Center, Cincinnati

   See if you can join NCT03178630 on ClinicalTrials.gov

5. A-LiNK: Improving Outcomes in Autoimmune Liver Disease

   The Autoimmune Liver disease Network for Kids (A-LiNK) is a multi-institutional group with the mission to deliver the best care to kids with pediatric autoimmune liver disease (AILD). This study will establish a shared clinical registry and a learning health network for the participating sites focu…

   Stage

   Not phased

   Ages

   Any age

   Site

   Stanford University, Palo Alto, California

   Locations

   8 in total

   Run by

   Children's Hospital Medical Center, Cincinnati

   See if you can join NCT05750498 on ClinicalTrials.gov

6. Detoxification of the Liver In PSC (Dolphin)

   This study is a clinical trial being done to investigate the efficacy of drug BRS201 (hydroxocobalamin) as a treatment in patients with primary sclerosing cholangitis. Participation in this study will take 8 weeks long and the study is structured as a cross-over study in which participants will tak…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Brigham and Women's Hospital, Chestnut Hill, Massachusetts

   Run by

   Brigham and Women's Hospital

   See if you can join NCT05835505 on ClinicalTrials.gov

7. Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation

   This study aims to determine the efficacy of 36 months once-daily fenofibrate in preventing clinically-detectable recurrence of primary sclerosing cholangitis after liver transplantation, compared with a historical control cohort that was not treated with

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Mayo Clinic in Arizona, Scottsdale, Arizona

   Run by

   Mayo Clinic

   See if you can join NCT06905054 on ClinicalTrials.gov

8. Primary Sclerosing Cholangitis in Children

   Primary sclerosing cholangitis (PSC) is a rare liver disease that damages the liver's bile ducts. Bile ducts are tiny tubes that carry bile from the liver to the small intestine. Bile is a liquid produced by the liver that helps us absorb and use the nutrients in the food we eat. In people with PSC…

   Stage

   Not phased

   Ages

   2 to 25

   Site

   Children's Hospital of Los Angeles, Los Angeles, California

   Locations

   12 in total

   Run by

   Arbor Research Collaborative for Health

   See if you can join NCT04181138 on ClinicalTrials.gov

9. Evaluation of an Oral Microbiota-based Therapeutic as a Treatment Option for PSC

   This pilot clinical trial will evaluate the initial safety and feasibility of microbiota transplant therapy (MTT) inpatients with primary sclerosing cholangitis (PSC). This trial will inform development of future trials in treatment of PSC.

   Stage

   EARLY_Phase 1

   Ages

   18 to 76

   Site

   University of Minnesota, Minneapolis, Minnesota

   Run by

   University of Minnesota

   See if you can join NCT06197308 on ClinicalTrials.gov

10. A Study of TAK-781 in Healthy Volunteers and in Participants With Non-Cirrhotic Primary Sclerosing Cholangitis (PSC)

    The main aim of this study is to see if the drug TAK-781 is safe for healthy volunteers and for participants with PSC. The study will also look at how well participants can tolerate TAK-781. In addition, the study will check how the body absorbs, uses, and gets rid of TAK-781 (Pharmacokinetics [PK]…

    Stage

    Phase 1

    Ages

    18 to 68

    Site

    ICON, Salt Lake City, Utah

    Run by

    Takeda

    See if you can join NCT07229911 on ClinicalTrials.gov

11. Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study

    PSC is a liver disease that has no medical cure. Patients with PSC are at a greatly increased risk of cancer and infection. Additionally, many patients require a liver transplant. Progress towards a cure has been severely limited by an incomplete understanding of why patients develop PSC. The inves…

    Stage

    EARLY_Phase 1

    Ages

    18 to 80

    Site

    Stanford University, Stanford, California

    Run by

    Stanford University

    See if you can join NCT05912387 on ClinicalTrials.gov

12. Biobank for Cholestatic Liver Diseases.

    This study is a biobank of specimens and clinical data for use in current and future research to better understand the cholestatic liver diseases primary biliary cirrhosis/cholangitis (PBC) and primary sclerosing cholangitis (PSC).

    Stage

    Not phased

    Ages

    18 to 85

    Site

    Mayo Clinic, Rochester, Minnesota

    Run by

    Mayo Clinic

    See if you can join NCT03445585 on ClinicalTrials.gov

13. Characterization of Biliary Cell-derived Organoids From Bile of PSC and Non-PSC Patients

    The purpose of this research is to create a collection of bile, bile duct brushings and medical information from people with Primary Sclerosing Cholangitis (PSC) and controls to learn more about changes that occur in the liver.

    Stage

    Not phased

    Ages

    18 to 85

    Site

    Mayo Clinic in Rochester, Rochester, Minnesota

    Run by

    Mayo Clinic

    See if you can join NCT04753996 on ClinicalTrials.gov

14. A Study of SIPLIZUMAB in AILD and LT Patients

    There is a significant unmet need for safe and effective therapeutic approaches to prevent immune-mediated graft injury and its complications in liver transplant (LT) recipients with autoimmune liver disease (AILD) including autoimmune hepatitis and primary sclerosing cholangitis. Siplizumab is an …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Columbia University Irving Medical Center/NewYork-Presbyterian Hospital, New York, New York

    Run by

    Elizabeth C. Verna

    See if you can join NCT06455280 on ClinicalTrials.gov

15. Oral Hymecromone to Treat Adolescents and Adults With Primary Sclerosing Cholangitis.

    Primary objective: To evaluate the efficacy of hymecromone plus standard of care compared with standard of care alone in the treatment of adolescents and adults with primary sclerosing cholangitis (PSC). Secondary objectives: To evaluate the change in Alkaline Phosphatase (ALP) from baseline to 6 m…

    Stage

    Phase 2

    Ages

    14 to 75

    Site

    Stanford Clinic, Redwood City, California

    Locations

    2 in total

    Run by

    Aparna Goel

    See if you can join NCT05295680 on ClinicalTrials.gov

16. Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin

    The purpose of this study is twofold. First, is to determine whether vancomycin is effective in the early treatment of Biliary Atresia (BA) and Primary Sclerosing Cholangitis (PSC), and if so, by what mechanism. Secondly, to characterize human intestinal microbial communities and their interactions…

    Stage

    Phase 1

    Ages

    0 to 40

    Site

    Sacramento Pediatric Gastroenterology, Sacramento, California

    Run by

    Sacramento Pediatric Gastroenterology

    See if you can join NCT02137668 on ClinicalTrials.gov